Extensive 177 Lu-PSMA Radioligand Therapy Can Lead to Radiation Nephropathy with a Renal Thrombotic Microangiopathy-like Picture

Lutetium-177 prostate-specific membrane antigen ( Lu-PSMA) radioligand therapy is an option that is increasingly being used for treatment of metastatic castration-resistant prostate cancer. This delivers β-radiation to cells expressing PSMA and high accumulation of the radiopharmaceutical occurs in...

Full description

Saved in:
Bibliographic Details
Published in:European urology 2023-05, Vol.83 (5), p.385
Main Authors: Schäfer, Hannah, Mayr, Sarah, Büttner-Herold, Maike, Knorr, Karina, Steinhelfer, Lisa, Böger, Carsten A, Gschwend, Jürgen E, Heemann, Uwe, Eiber, Matthias, Schmaderer, Christoph, Tauber, Robert
Format: Article
Language:English
Subjects:
Dipeptides
Humans
Kidney - pathology
Lutetium - therapeutic use
Male
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant - pathology
Prostatic Neoplasms, Castration-Resistant - radiotherapy
Thrombotic Microangiopathies
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lutetium-177 prostate-specific membrane antigen ( Lu-PSMA) radioligand therapy is an option that is increasingly being used for treatment of metastatic castration-resistant prostate cancer. This delivers β-radiation to cells expressing PSMA and high accumulation of the radiopharmaceutical occurs in the kidneys. Here we report three cases of radiation nephropathy with severe chronic kidney disease induced by renal thrombotic microangiopathy following extensive treatment with Lu-PSMA radioligand therapy.
ISSN:1873-7560